Modeling the emergence of the 'hot zones': Tuberculosis and the amplification dynamics of drug resistance

Nature Medicine

Volumn 10, Issue 10, 2004, Pages 1111-1116

  Blower, Sally M ^a   Chou, Tom ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

AMPLIFIER MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; HUMAN; INCIDENCE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RISK FACTOR; STRAIN IDENTIFICATION; TUBERCULOSIS; WILD TYPE; WORLD HEALTH ORGANIZATION;

DISEASE OUTBREAKS; EPIDEMIOLOGIC RESEARCH DESIGN; EVOLUTION; GEOGRAPHY; HUMANS; INCIDENCE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

ACTINOBACTERIA (CLASS); MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 7044234498     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1102     Document Type: Article

References (36)

1. Iseman, M.D. Evolution of drug-resistant tuberculosis: a tale of two species. Proc. Natl. Acad. Sci. USA 91, 2428-2429 (1994).
2. Iseman, M.D. Tuberculosis therapy: past, present and future. Eur. Respir. J. 36, 87s-94s (2002).
3. Reichman, L. & Tanne, J.H. Timebomb: The Global Epidemic of Multi-Drug-Resistant Tuberculosis (McGraw-Hill, New York, 2002).
4. Dye, C., Espinal, M.A., Watt, C.J., Mbiaga, C. & Williams, B.G. Worldwide incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 185, 1197-1202 (2002).
5. Espinal, M.A. et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 344, 1294-1303 (2001).
6. Pablos-Méndez, A. et al. Anti-tuberculosis drug resistance in the world. Report 1 (World Health Organization, Geneva, 2000).
7. Farmer, P.E., Reichman, L. & Iseman, M.D. Report: The global impact of drug-resistant tuberculosis (Harvard Medical School, Open Society Institute, Cambridge, Massachusetts, USA, 1999).
8. Espinal, M.A. et al. Anti-tuberculosis drug resistance in the world. Report no. 2: Prevalence and trends (World Health Organization, Geneva, 2003).
9. Farmer, P.E. et al. The dilemma of MDR-TB in the global era. Int. J. Tuberc. Lung. Dis. 2, 869-876 (1998).
10. Mitnick, C. et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348, 119-128 (2003).
11. Blower, S.M. & Daley, C.L. Problems and solutions for the Stop TB partnership. Lancet Infect. Dis. 2, 374-376 (2002).
12. Espinal, M.A. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int. J. Tuberc. Lung. Dis. 7, 607-608 (2003).
13. Blower, S.M., Small, P.M. & Hopewell, P.C. Control strategies for tuberculosis epidemics: new models for old problems. Science 273, 497-500 (1996).
14. Blower, S.M. & Gerberding, J.L. Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. J. Mol. Med. 76, 624-636 (1998).
15. Blower, S.M., Porco, T.C. & Lietman, T. Tuberculosis: the evolution of antibiotic resistance and the design of epidemic control strategies, in Mathematical Models in Medical and Health Sciences (eds. Horn, Simonett & Webb) (Vanderbilt University Press, Nashville, TN, 1998).
16. Blower, S.M., Koelle, K. & Lietman, T. Antibiotic resistance-to treat... Nat. Med. 5, 358 (1999).
17. Castillo-Chavez, C. & Feng, Z. To treat or not to treat: the case of tuberculosis. J. Math. Biol. 35, 629-656 (1997).
18. Dye, C. & Williams, B.G. Criteria for the control of drug-resistant tuberculosis. Proc. Natl. Acad. Sci. USA 97, 8180-8185 (2000).
19. Hopewell, P.C. Tuberculosis control: how the world has changed since 1990. Bull. World Health Organ. 80, 427 (2002).
20. Frieden, T., Sterling, T., Munsiff, S., Watt, C.J. & Dye, C. Tuberculosis. Lancet 362, 887-899 (2003).
21. Blower, S.M. & Dowlatabadi, H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Inter. Stat. Rev. 2, 229-243 (1994).
22. Blower, S.M. et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat. Med. 1, 815-821 (1995).
23. Sanchez, E. & Blower, S.M. Uncertainty and sensitivity analysis of the basic reproductive rate. Tuberculosis as an example. Am. J. Epidemiol. 145, 1127-1137 (1997).
24. Porco, T.C. & Blower, S.M. Quantifying the intrinsic transmission dynamics of tuberculosis. Theo. Pop. Bio. 54, 117-132 (1998).
25. Blower, S.M., Porco, T.C. & Darby, G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat. Med. 4, 673-678 (1998).
26. Bankes, S. Tools and techniques for developing policies for complex and uncertain systems. Proc. Natl. Acad. Sci. USA 99 (Suppl. 3), 7263-7266 (2002).
27. Elzinga, G., Raviglione, M.C. & Maher, D. Scale up: meeting targets in global tuberculosis control. Lancet 363, 814-819 (2004).
28. Mukherjee, J.S. et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363, 474-481 (2004).
29. Lietman, T. & Blower, S.M. The potential impact of tuberculosis vaccines as epidemic control agents. Clin. Infect. Dis. 30, S316-S322 (2000).
30. Porco, T.C., Small, P.M. & Blower, S.M. Amplification dynamics: Predicting the effect of HIV on tuberculosis outbreaks. J. Acquir. Immune Defic. Syndr. 28, 437-444 (2001).
31. Ziv, E., Daley, C.L. & Blower, S.M. Early therapy for latent tuberculosis infection. Am. J. Epidemiol. 153, 381-385 (2001).
32. Sterling, T., Lehmann, H. & Frieden, T. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 326, 574 (2003).
33. Centers for Disease Control. Primary multidrug-resistant tuberculosis-Ivanovo Oblast, Russia, 1999. MMWR 48, 661-663 (1999).
34. Migliori, G. et al. Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. Int. J. Tuberc. Lung. Dis. 6, 858-864 (2002).
35. Suarez, P. et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359, 1980-1989 (2002).
36. Cohen, T., Sommers, B. & Murray, M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 3, 13-21 (2003).